After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Dayrttnews·10 hours agoPFSA+25.87%GNPX+3.59%
How Investors May Respond To Labcorp (LH) Expanding PTEN Dx Reach Amid Oncology Leadership TransitionSimplywall·12 hours agoLH+1.64%RHHBY+0.17%
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesMarket Beat·1 day ago, 12:01 AMRXRX-1.58%SNY+1.58%
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q SummaryTradingView·Aug 10 at 08:11 AMMAIA-0.71%REGN+0.30%
ChemoMetec, Roche Diagnostics partner to develop connectivity kit for bioprocess analyzersPUBT·Aug 10 at 05:32 AMRHHBY+0.17%
Prothena publishes corporate overview presentation on protein-dysregulation drug pipelinePUBT·Aug 6 at 04:33 PMPRTA+0.23%NVO-0.95%
Prothena Q2 FY26 net loss narrows to $18.6 million; revenue drops to $1 millionPUBT·Aug 6 at 03:22 PMPRTA+0.23%RHHBY+0.17%
Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrantWorldPharmaceuticals·Aug 5 at 05:34 AMRHHBY+0.17%
Recursion Q2 net loss narrows to $131.01 million; revenue drops to $7.67 millionPUBT·Aug 5 at 05:31 AMRXRX-1.58%RHHBY+0.17%
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast CancerUnusual Whales·Aug 4 at 02:02 AMRHHBY+0.17%
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update | IDYA Stock NewsStockTitan·Aug 3 at 09:00 PMIDYA+0.66%RHHBY+0.17%
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies | GNPX Stock NewsStockTitan·Aug 2 at 10:00 PMGNPX+3.59%RHHBY+0.17%
12:00 ETADLM announces 2026 Top Corporate Supporter Award recipients and thanks them for their essential backingprnewswire·Jul 28 at 11:01 AMDHR+0.09%ABT-0.79%
Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings NarrativesSimplywall·Jul 24 at 04:17 PMRHHBY+0.17%
